Category: Federal Forum Posters
Purpose: Atherosclerotic cardiovascular disease (ASCVD) is a common condition that can lead to clinically significant events such as myocardial infarctions, cerebrovascular events, and chronic angina. Upon experiencing such events, individuals are at an increased risk of secondary occurrences. Therefore, practice guidelines recommend reducing this risk by lowering low density lipoprotein (LDL) levels. Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK-9 inhibitors) are proven to lower LDL up to 60%. The purpose of this project is to utilize a risk assessment tool to recommend the initiation of a PCSK-9 inhibitor in high risk veterans currently treated with a high intensity statin.
Methods: The computerized patient record system (CPRS) will be used to identify high risk veterans with clinical ASCVD via international classification of diseases (ICD-9 and ICD-10) diagnosis codes. The identified veterans will be reviewed for current treatment with a high-intensity statin (atorvastatin 40-80mg, rosuvastatin 20-40mg) along with a baseline LDL ≥100 mg/dl. A risk assessment tool will be created to assess if the veterans are eligible to receive a PCSK-9 inhibitor for the prevention of secondary cardiovascular events. This tool will outline the key risk factors, indications, and contraindications to initiating PCSK-9 inhibitors. To aid in the standardization of initiating therapy, clinical providers and pharmacists will be educated on the current strategies for secondary cardiovascular event prevention, specifically related to the use of PCSK-9 inhibitors and their effectiveness in high risk patients.
Results: not applicable
Conclusion: not applicable
Nieka Jackson– PGY1 Pharmacy Practice Resident, Carl Vinson Veterans Affairs Medical Center, Dublin, GA